Let's not for­get why bio­phar­ma megamerg­ers are such an aw­ful idea

End­points as­sess­es the big bio­phar­ma R&D sto­ries of the week, with a lit­tle added com­men­tary on what they mean for the in­dus­try.

A Bris­tol-My­ers Squibb takeover? Not a great idea

This week mur­murs about a pos­si­ble takeover of Bris­tol-My­ers Squibb turned in­to a shout af­ter Carl Ic­ahn re­port­ed­ly stepped up to buy in­to the big biotech. Af­ter a se­ries of painful set­backs on Op­di­vo, BMS has sud­den­ly trad­ed in its white hat for a black one as in­vestors switched al­le­giance to Mer­ck.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.